Metabolic diseases from the point of view of the gut bacterial motility and mucu...
Metabolic diseases from the point of view of the gut bacterial motility and mucus barrier
MEDMOTILUS aims to uncover the alterations of gut mucus/microbiota homeostasis in metabolic diseases and therapeutic targets using human data and animal models. It will fill research gaps in the multiple scenarios of metabolic dis...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2017-87958-P
LA INTERACCION ENTRE MICROBIOTA Y METABOLISMO DEL HUESPED RE...
206K€
Cerrado
MUTFLYGUTBACT
Host intestinal bacteria mutualism Learning on the fly...
1M€
Cerrado
AGL2010-16525
MECANISMOS DE INTERACCION ENTRE BIFIDOBACTERIAS Y SUS EXOPOL...
157K€
Cerrado
Mucus and Metabolism
The relationship between the intestinal mucosal barrier and...
198K€
Cerrado
AGL2016-78311-R
NUEVOS METODOS PARA EL CULTIVO Y CARACTERIZACION DE PROBIOTI...
278K€
Cerrado
PID2019-107327RB-I00
EVALUACION DE NUEVAS ACTIVIDADES DE VESICULAS SECRETADAS POR...
182K€
Cerrado
Información proyecto MEDMOTILUS
Duración del proyecto: 37 meses
Fecha Inicio: 2021-04-19
Fecha Fin: 2024-05-31
Líder del proyecto
SORBONNE UNIVERSITE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
185K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
MEDMOTILUS aims to uncover the alterations of gut mucus/microbiota homeostasis in metabolic diseases and therapeutic targets using human data and animal models. It will fill research gaps in the multiple scenarios of metabolic diseases, one of the greatest threats to human health. The gut microbiota is a key environmental factor of these diseases, and its modulation is a potential treatment. However, the host-microbiota interactions are far from being fully described. The gut mucus barrier is a host spatial control that plays a crucial role in the microbiota regulation but poorly understood. Diet and medicines may affect this defense and, thus, improving metabolism and reducing gut bacterial motility, whose increase is linked to health disorders even without serious infections. However, there is no in-depth bacterial motility characterization in metabolic diseases and no data on mucus features nor on its effect on bacteria in these diseases. So, the overall research goal of MEDMOTILUS is to provide evidence of the impact of gut bacterial motility and mucus in metabolic diseases as key factors involving dysbiosis, mucus features, and metabolic status. MEDMOTILUS takes a multidisciplinary approach. It will go beyond the current state-of-the-art by using original input data (bacterial motility from modeling and mucus features) with multi-omic approaches (also metabolomics and metagenomics). Several potential solutions acting on mucus will be assessed in mice. The use of human data already generated and animal models (mice and a new pig model) will allow me to identify robust and useful biomarkers of the gut mucus/microbiota homeostasis in metabolic diseases for further research on diagnosis and monitoring to reduce long-term complications and deaths. At the level of my career, MEDMOTILUS will allow me to enhance my research profile and network, strongly impacting my chances of achieving my long-term goal to become a Professor and develop a prolific scientific career.